Flow Neuroscience
Transformational mental health treatment platform with FDA Breakthrough Designation and medical device certification in the EU.
Expertise in medical-grade, at-home neuromodulation.
At-home treatment for depression
that is free of side effects
>12,000 users to date, live in 100+ clinics and hospitals
with EU reimbursement coverage for over 2 million lives and 3 NHS Health Outcomes studies
Clinically validated:
Technology validated across 32 peer-reviewed studies. EU/UK regulatory approved, targeting FDA approval in Q4
2x more effective than antidepressants, without the side effects
demonstrated in largest controlled clinical trial of its kind
Investors
Raised to date: $16m Series A. Founded in 2016.
Erin Sivyer Lee, CEO
Erin is an experienced executive who has spent 20+ years building exceptional global teams for some of the world’s largest and fastest-growing consumer technology companies, including Uber, Google, and most recently, Babylon Health, where she led global operations and expansion of the business.
Erin’s goal is to bring world class customer experiences to the healthcare industry. Few things are more precious than health and the average experience for patients today is stressful, confusing and lacks personalised care. Erin is committed to bringing this change across mental disorders, particularly for depression and addiction where current solutions are woefully inadequate with very few accessible medication-free options.
Daniel Månsson, CCO and Co-founder
As a Clinical Psychologist with over 10 years of brain stimulation research and a background in Computer Science, Daniel has made it his mission to merge technology with psychology to treat mental health across the world.
As a result of this mission, Daniel co-founded Flow Neuroscience, a neurotech company with a focus on rigorous science, empowerment and accessibility. The first product born from this was Flow, the only medically-certified device to treat Major Depressive Disorder combining brain stimulation with behavioural therapy.
Personally, Daniel wants to normalise conversations towards mental health, question traditional methods of treating mental diseases and make real progress towards treating everyone that is suffering.
Erik Rehn, CTO and Co-founder
As a master of Computational Neuroscience and experienced founder of two technology startups, Erik has always been a keen innovator, looking at how we can use AI and other technologies to create science transfer with a human focus.
This led Erik to co-found Flow Neuroscience, a neurotech company with a focus on empowerment, accessibility and science.
Personally, Erik wants to drive innovation in mental health by utilising revolutionary technologies to understand the brain’s role in altering human circumstance.
Sam Lowden, Head of Growth
Sam joined Flow Neuroscience in early 2022 as Flow’s Head of Growth.
Sam has 10+ years of experience in Growth, Commercial and Marketing roles. Prior to Flow, Sam worked at Babylon Health, where he was responsible for driving acquisition and engagement for digital health products, and BP, where he drove operational expansion to new areas.
Nic Lowden, Head of Finance & Corp Dev
Nic joined Flow Neuroscience in early 2022 and is responsible for financial reporting, business planning, and fundraising.
Nic has worked with Flow’s CEO - Erin Lee - for over eight years, having worked with Erin at Babylon Health and Uber, where he worked in financial planning and fundraising roles. Before this, Nic worked in mergers and acquisitions and equity capital markets at Credit Suisse, covering healthcare and technology companies. Nic holds an MSc in Mathematics from Cambridge University.
Supported by the world’s leading experts in Psychiatry and Neuromodulation
Andrew A. Nierenberg MD, PhD
Professor of Psychiatry at Harvard University. Ranked top 1% of researchers for most cited papers in psychiatry worldwide; published > 500 papers
Allan Young MB, PhD
Professor of Psychiatry at King’s College London Listed as World’s Most Influential Scientific Minds. Chair of Mood Disorders & Director of Centre for Affective Disorders (Psychiatry) at King’s
Corey Keller MD, PhD
Assistant Professor of Psychiatry Stanford University Leads the Stanford Laboratory for Personalized Neurotherapeutics. Former CMO of Alto Neuroscience
Joan Camprodon-Gimenez MD, PhD, MPH
Associate Professor of Psychiatry Harvard University Founding director of TMS service at Massachusetts General Hospital
André Russowsky Brunoni MD, PhD
Associate Professor University of São Paulo Leading researcher in Neuromodulation.